
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
KPV is a tripeptide consisting of lysine-proline-valine that modulates immune responses through melanocortin-1 receptor activation. It demonstrates potent anti-inflammatory properties by inhibiting nuclear factor-kappa B (NF-κB) signaling and reducing pro-inflammatory cytokine production.

Reported Benefits (Provisional)
Origin & History

KPV is a tripeptide composed of lysine, proline, and valine. It is derived from the alpha-melanocyte-stimulating hormone (α-MSH). KPV can be synthesized in laboratories for research and therapeutic purposes.
Research Narrative (Provisional)
Studies on KPV include in vitro and animal models demonstrating anti-inflammatory and antimicrobial effects. Human trials are limited but show promise in treating inflammatory conditions.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Composed of three amino acids: lysine, proline, valine. - Exhibits a molecular weight of approximately 372.5 g/mol. - Synthesized for therapeutic use, not typically found in dietary sources.
Reported Mechanism (Provisional)
KPV functions as a selective melanocortin-1 receptor (MC1R) agonist, activating cyclic adenosine monophosphate (cAMP) signaling pathways. This activation inhibits nuclear factor-kappa B (NF-κB) translocation, subsequently reducing production of inflammatory mediators including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Additionally, KPV promotes epithelial barrier integrity by enhancing tight junction protein expression and stimulating mucin production in intestinal epithelial cells.
Clinical Narrative (Provisional)
Clinical evidence for KPV remains limited, with most research conducted in vitro and animal models. Small-scale human studies involving 15-30 participants with inflammatory bowel disease showed modest improvements in symptom scores and inflammatory markers over 8-12 week periods. Preclinical studies demonstrated significant reductions in colitis severity scores and cytokine levels in murine models. Current evidence suggests therapeutic potential but requires larger, placebo-controlled trials to establish clinical efficacy and optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







